This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Short-Squeeze Stocks Primed to Pop

Quest Diagnostics

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Investors hate medical testing company Quest Diagnostics ( DGX). With a short ratio of 12.26, investors hate this stock so much, in fact, that it would take two-and-a-half weeks of buying pressure at current volume levels for shorts to cover their bets. That makes Quest a large-cap short squeeze candidate this week.

>>5 Rocket Stocks to Buy After the Selloff

Quest provides clinical testing at a network of 2,000 locations across the country. If you've taken a blood test or a drug screening in the last few years, there's a good chance it was at one of Quest's facilities. There's a lot to like about this company right now: It's recession resistant (physicians' blood work orders don't ebb and flow with the economy), margins are thick, and an aging population should boost demand for DGX's services. That's particularly true if Obamacare increases the number of insured patients in the U.S.

Quest has been adding some new tests to its menu in recent years. The addition of more complex products like genetic and pathological tests require more advanced equipment and additional technicians, but they also provides a huge shot in the arm for net margins. In the meantime, renegotiated managed care contracts should help correct the falling margins in Quest's older, standard tests.
5 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
DGX $62.10 2.60%
LBTYA $31.54 1.10%
MTB $105.43 -1.90%
RMD $57.74 0.98%
SYY $42.70 0.21%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs